Chronic inflammation exacerbates T2DM, as demonstrated in the CANTOS trial, where IL-1β inhibition with canakinumab reduced HbA1c by 0.5% and cardiovascular events by 15% [3]. The gene discussed is IL1B; the disease is type 2 diabetes mellitus.